ADC Therapeutics SA

ADCT

CH0499880968

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:03:35 2024-05-17 pm EDT			5-day change	1st Jan Change
4.04 ^USD	-1.22%		-6.28%	+142.77%

May. 07	HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating	MT
May. 06	Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday	MT

ADC Therapeutics SA Announces Resignation of Dominique Graz as General Counsel and Secretary, Effective September 30, 2020

August 14, 2020 at 04:34 pm EDT

ADC Therapeutics SA announced resignation of Dominique Graz as General Counsel and Secretary to pursue a new opportunity, effective September 30, 2020.

Latest news about ADC Therapeutics SA

HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating	May. 07	MT
Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday	May. 06	MT
ADC Therapeutics Launches $105 Million Offering; Shares Up 2% Pre-Bell	May. 06	MT
Transcript : ADC Therapeutics SA, Q1 2024 Earnings Call, May 06, 2024	May. 06
ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial	May. 06	MT
ADC Therapeutics SA Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma	May. 06	CI
Transcript : ADC Therapeutics SA - Special Call	Apr. 09
Sector Update: Health Care Stocks Slump Late Afternoon	Apr. 04	MT
ADC Therapeutics Shares Rise After Completion of Dose Escalation Part of Phase 1b Lymphoma Trial	Apr. 04	MT
Chiome Bioscience Cancels License Agreements with ADC Therapeutics	Mar. 31	MT
Guggenheim Initiates ADC Therapeutics With Buy Rating, $11 Price Target	Mar. 28	MT
Transcript : ADC Therapeutics SA, Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
ADC Therapeutics SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
ADC Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
RBC Lifts Price Target on ADC Therapeutics to $8 From $6, 'Encouraged' by Competitive Positioning; Outperform, Speculative Risk Kept	Feb. 26	MT
HC Wainwright Raises Price Target on ADC Therapeutics to $9 From $3, Maintains Buy Rating	Feb. 20	MT
Certain Common Shares of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Certain Restricted Stock Units of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Certain Warrants of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
Certain Options of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	Feb. 02	CI
ADC Therapeutics SA Enters First Amendment to the Loan Agreement	Jan. 19	CI
ADC Therapeutics Regains Compliance With NYSE Continued Listing Standards	Jan. 04	MT
HC Wainwright Adjusts Price Target on ADC Therapeutics to $3 From $12, Keeps Buy Rating	Nov. 20	MT
TD Cowen Downgrades ADC Therapeutics to Market Perform From Outperform	Nov. 09	MT

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkinâs lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - H.C. Wainwright BioConnect Investor Conference

More about the company

Income Statement Evolution

More financial data

Ratings for ADC Therapeutics SA

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.09 USD

Average target price

10 USD

Spread / Average Target

+144.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADC THERAPEUTICS SA	+142.77%	393M
VERTEX PHARMACEUTICALS INCORPORATED	+8.71%	114B
REGENERON PHARMACEUTICALS, INC.	+11.27%	104B
BIONTECH SE	-12.73%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.07%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+8.01%	14.28B
SAREPTA THERAPEUTICS, INC.	+35.27%	12.55B

Bio Therapeutic Drugs